Cellectis (CLLS) Interest & Investment Income (2022 - 2026)
Cellectis' (CLLS) quarterly Interest & Investment Income came in at $11.9 million in Q1 2026, up 88.84% year-on-year from $6.3 million in Q1 2025, and up 489.93% quarter-over-quarter from $2.0 million in Q4 2025.
Cellectis (CLLS) Interest & Investment Income (2022 - 2026) Analysis & Trends
Cellectis' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 88.84% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $22.9 million, a 29.36% decrease from a year earlier, with the FY2025 full-year figure at $16.1 million, down 63.69% from the prior year.
- Interest & Investment Income rose to $11.9 million in Q1 2026 per CLLS's latest filing, from $2.0 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $29.4 million in Q1 2024 and bottomed at -$6.3 million in Q4 2022.
- The 5-year median for Interest & Investment Income is $5.3 million (2023), against an average of $6.8 million.
- Across the five-year window, Interest & Investment Income jumped 3694.84% in 2024 and sank 86.27% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at -$6.3 million in 2022, then surged by 185.15% to $5.3 million in 2023, then soared by 174.6% to $14.7 million in 2024, then sank by 86.27% to $2.0 million in 2025, then surged by 489.93% to $11.9 million in 2026.
- Per Business Quant, the three latest CLLS Interest & Investment Income figures stand at $11.9 million (Q1 2026), $2.0 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | 11.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.89 Mn |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Dec 31, 2024 | 14.68 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 8.40 Mn |
| Mar 31, 2024 | 29.41 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Jun 30, 2023 | 10.44 Mn |
| Mar 31, 2023 | 775,000.00 |
| Dec 31, 2022 | -6.28 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 9.99 Mn |
| Mar 31, 2022 | 2.27 Mn |